Products for Research Use Only

JAK-IN-23

CAT: 0804-HY-151262-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-151262-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
JAK-IN-23 is an orally active double inhibitor of JAK/STAT and NF-κB. JAK-IN-23 can inhibit JAK1/2/3 with IC50 values of 8.9 nM, 15 nM and 46.2 nM, respectively. JAK-IN-23 has potent inhibitory activities against interferon-stimulated genes (ISG) and NF-κB pathways with IC50 values of 3.3 nM and 150.7 nM, respectively. JAK-IN-23 has great anti-inflammatory that decreases the release of various proinflammatory factors. JAK-IN-23 can be used for the research of inflammatory bowel disease (IBD) [1].
CAS Number
3031837-35-8
UNSPSC
12352005
Target
JAK; NF-κB; STAT; STING
Type
Reference compound
Related Pathways
Epigenetics; Immunology/Inflammation; JAK/STAT Signaling; NF-κB; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/jak-in-23.html
Purity
98.88
Solubility
DMSO : 5 mg/mL (ultrasonic; warming; heat to 80°C)
Smiles
OC1=C(Cl)C=C(C2=CC=C3N=CC(N=C(C)N4C5CCN(C)CC5)=C4C3=C2)C=C1Cl
Molecular Formula
C23H22Cl2N4O
Molecular Weight
441.35
References & Citations
[1]Xuewu Liang, et al. Discovery of Novel Imidazo[4,5- c]quinoline Derivatives to Treat Inflammatory Bowel Disease (IBD) by Inhibiting Multiple Proinflammatory Signaling Pathways and Restoring Intestinal Homeostasis. J Med Chem. 2022 Sep 2.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, sealed storage, away from moisture and light)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
JAK1; JAK2; JAK3; NF-κB

Popular Products